STOCK TITAN
  1. Home
  2. Sec-filings
  3. BHVN
  4. [Form 4] Biohaven Ltd. Insider Trading Activity

Biohaven (BHVN) SVP Reports RSU Vesting and Tax Withholding

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Biohaven Ltd. senior vice president of clinical operations Kimberly Gentile reported routine equity transactions tied to restricted share units. On January 5, 2026, 3,750 restricted share units converted into the same number of common shares at an exercise price of $0, increasing her directly held stake. To cover tax withholding on this vesting, 1,956 common shares were withheld by the company at a price of $9.93 per share, with no shares sold into the market. After these transactions, Gentile directly owned 99,557 common shares and held 7,500 restricted share units, which represent the right to receive additional common shares as future vesting dates are met.

Positive

  • None.

Negative

  • None.
Insider Gentile Kimberly
Role SVP, Clinical Operations
Type Security Shares Price Value
Exercise Restricted Share Unit Award 3,750 $0.00 --
Exercise Common Shares 3,750 $0.00 --
Tax Withholding Common Shares 1,956 $9.93 $19K
Holdings After Transaction: Restricted Share Unit Award — 7,500 shares (Direct); Common Shares — 101,513 shares (Direct)
Footnotes (1)
  1. No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Each restricted share unit represents the contingent right to receive one common share of the Issuer. The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. Not applicable.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gentile Kimberly
(Last) (First) (Middle)
C/O BIOHAVEN LTD.
215 CHURCH STREET
(Street)
NEW HAVEN CT 06510
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Clinical Operations
3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/05/2026 M 3,750 A $0 101,513 D
Common Shares 01/05/2026 F 1,956(1) D $9.93 99,557 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Unit Award (2) 01/05/2026 M 3,750 (3) (4) Common Shares 3,750 $0(2) 7,500 D
Explanation of Responses:
1. No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
2. Each restricted share unit represents the contingent right to receive one common share of the Issuer.
3. The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
4. Not applicable.
Remarks:
/s/ George Clark, Attorney-in-Fact 01/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this Biohaven (BHVN) Form 4 filing and what is their role?

The insider is Kimberly Gentile, who serves as SVP, Clinical Operations at Biohaven Ltd. and is reporting equity transactions in the company’s shares.

What equity transaction did Kimberly Gentile report for Biohaven (BHVN) on January 5, 2026?

On January 5, 2026, 3,750 restricted share units converted into 3,750 common shares of Biohaven at an exercise price of $0 per share.

Were any Biohaven (BHVN) shares actually sold by the insider in this filing?

No shares were sold. A total of 1,956 common shares were withheld by the issuer to satisfy tax withholding requirements related to the vesting of restricted share units.

How many Biohaven (BHVN) common shares does Kimberly Gentile own after these transactions?

Following the reported transactions, Kimberly Gentile directly owns 99,557 common shares of Biohaven Ltd.

How many restricted share units does the insider still hold after the January 5, 2026 Biohaven (BHVN) transaction?

After the January 5, 2026 vesting, she beneficially owns 7,500 restricted share units, each representing the contingent right to receive one Biohaven common share.

What was the original Biohaven (BHVN) restricted share unit grant to Kimberly Gentile?

Kimberly Gentile was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, subject to continued service.

How are the tax obligations handled for Kimberly Gentile’s Biohaven (BHVN) RSU vesting?

For the January 5, 2026 vesting, 1,956 shares were withheld by Biohaven at $9.93 per share to satisfy tax withholding requirements related to the vested restricted share units.